Labopharm Europe opens new hq in Dublin

Published: 28-Jan-2004

Labopharm Europe, a wholly owned subsidiary of Canada-based Labopharm Inc. has officially opened its new head office in Dublin, Ireland.


Labopharm Europe, a wholly owned subsidiary of Canada-based Labopharm Inc. has officially opened its new head office in Dublin, Ireland.

Labopharm is nearing commercialisation of its first product, a once-daily formulation of the analgesic tramadol. In Europe, tramadol is currently available in generic immediate-release formulations that require dosing up to six times daily and branded sustained-release formulations that require twice-daily dosing.

In March 2003, Labopharm initiated the regulatory approval process in Europe for once-daily tramadol, commencing the Mutual Recognition Procedure (MRP) with the submission of a Marketing Authorisation Application (MAA) with regulatory authorities in France. Under the MRP, approval in France should facilitate rapid approval across the rest of the European Union and in many non-EU countries.

Labopharm Europe has been responsible for securing licensing and distribution agreements for once-daily tramadol in 18 European countries, including France (with Aventis France), Italy (with Gruppo Angelini), Spain and Portugal (with Esteve) and 14 Eastern European countries with CSC Pharmaceuticals.

'With a critical mass of expertise in the speciality pharma sector, Dublin is the ideal location for Labopharm Europe's new headquarters,' said James F.X. Fahy, director, Labopharm Europe. 'We look forward to continuing to build relationships, both within the local pharmaceutical community and across Europe, as we work towards the European commercialisation of Labopharm's once-daily formulation of tramadol and build Labopharm's presence internationally.'

  

You may also like